key: cord-0970528-x3r2f0zt
authors: Portilho, Amanda I.; Silva, Valéria O.; Ahagon, Cintia M.; Matsuda, Elaine M.; de Oliveira, Elaine L.; da Silveira, Edilene P. R.; de Souza Lima, Ana K.; Lindoso, José A. L.; de Campos, Ivana B.; Hong, Marisa A.; De Gaspari, Elizabeth; de Macedo Brígido, Luís F.
title: Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS‐CoV‐2 infection
date: 2021-08-26
journal: J Med Virol
DOI: 10.1002/jmv.27290
sha: 49c9c0aaace1e0ffe2fd7383517b58c338fec8da
doc_id: 970528
cord_uid: x3r2f0zt

Many aspects of the humoral immune response to severe acute respiratory syndrome coronavirus 2 (SARS‐CoV‐2), such as its role in protection after natural infection, are still unclear. We evaluated IgA and IgG response to spike subunits 1 and 2 (S1 and S2) and Nucleocapsid proteins of SARS‐COV‐2 in serum samples of 109 volunteers with viral RNA detected or seroconversion with different clinical evolution (asymptomatic, mild, moderate, and severe coronavirus disease 2019), using the ViraChip® Test Kit. We observed that the quantification of antibodies to all antigens had a positive correlation to disease severity, which was strongly associated with the presence of comorbidities. Seroreversion was not uncommon even during the short (median of 77 days) observation, occurring in 15% of mild‐asymptomatic cases at a median of 55 days for IgG and 46 days for IgA. The time to reach the maximal antibody response did not differ significantly among recovered and deceased volunteers. Our study illustrated the dynamic of anti‐S1, anti‐N, and anti‐S2 IgA and IgG antibodies, and suggests that high production of IgG and IgA does not guarantee protection to disease severity and that functional responses that have been studied by other groups, such as antibody avidity, need further attention.

The impact of this pandemic turns laboratory markers of disease, such as antibody tests, into a potential instrument to help in the monitoring of the epidemic. 2 SARS-CoV-2 expresses, among others, three antigens that are highly immunogenic and capable of inducing humoral immune response: S1 and S2 (subunits of spike) and N (nucleocapsid) glycoproteins.³ Spike is a transmembrane protein that binds at angiotensinconverting enzyme 2 or CD147 receptor expressed on the host cell's surface, through its receptor-binding protein (RBD), present in the S1 subunit, whilst S2 subunit mediates the fusion between viral and cellular membranes. N protein binds to the RNA and acts on virion assembly. 3, 4 COVID-19 presents a wide clinical spectrum that ranges from asymptomatic to mild disease of the upper respiratory tract, or moderate to severe disease with respiratory distress and multiple organ failure requiring intensive care and organ support. 5, 6 The role of antibody titer and of immunoglobulin classes involved in immune response may be useful to better elucidate the humoral features of COVID-19, as it might support clinical management and may tailor vaccine development. Our study aimed to evaluate the IgA and IgG response against S1, S2, and N proteins in individuals with confirmed SARS-CoV-2 infection (positive viral RNA) according to different clinical presentations (asymptomatic, mild, moderate, and severe COVID-19).

The study was approved by the institutional ethical committees, 

SARS-CoV-2 RNA was obtained for quantitative reversetranscription polymerase chain reaction (RT-qPCR) from nasopharyngeal and/or oropharyngeal secretions either by regular swab collection method, 9 or gargle throat wash, 10 and diagnosis was based on Charité protocol. 11 The samples with amplification in one or more of the three viral targets (E, RdRP, and N) with cycle thresholds (CTs) up to 37 were considered positive.

Specific antibodies to SARS-CoV-2 were detected using two different commercial kits: Electrochemiluminescence assay (ECLIA) Elecsys ® Anti-SARS-CoV-2 (Roche Diagnostics), which uses N as antigen, and chemiluminescence assay (CLIA) VITROS ® Anti-SARS-CoV-2 (Ortho Clinical Diagnostics), which uses S1 as antigen, both detect IgG antibodies. Assays were performed following the manufacturer's instructions and used to select PCR-negative cases.

The SARS-CoV-2 ViraChip ® Test Kit is a microarray based on an enzyme-immunoassay for the detection of IgG or IgA antibodies against SARS-CoV-2 antigens in human serum. This test uses purified S1, S2, and N antigens of SARS-CoV-2 spotted at defined positions on nitrocellulose membrane fixed at the bottom of each well of a standard plate. 12 The assay was performed following the manufacturer's instructions. Scanning was performed using SensoSpot ® Colorimetry MicroArray Analyzer (Sensovation) and analyzed using the ViraChip ® Software (ViraMed Biotech). Quantification is measured in ViraChip ® units. According to manufacturer criteria, a sample is positive for SARS-CoV-2 ViraChip ® IgG when one or more spots are more than or equal to 100 ViraChip ® units; and for SARS-CoV-2 ViraChip ® IgA, when two or more spots are more than or equal to 100 ViraChip ® units. Readings less than 70 are considered negative and from 70 to 99, inconclusive.

Categorical variables were compared by the Pearson's χ 2 test or Fisher's exact test as appropriate. Continuous variables were presented as range, median, and interquartile range (IQR 25th-75th).

Mann-Whitney or Kruskal-Wallis tests were used to compare groups. A two-sided p value less than or equal to 0.05 was considered significant. Statistical analysis was performed using the software STATA version 13 (StataCorp LP) and GraphPad Prism version 5 (GraphPad Softwares Inc). The most frequent symptoms reported were headache (39%), fatigue (33%), anosmia and/or dysgeusia (30%), and cough (28%).

The patients' information is shown in Table 1 .

Two classes of immunoglobulins, G (IgG) and A (IgA), were analyzed to assess the immune response to three SARS-CoV-2 antigens (S1, N, and S2 

In our study, seventy-five individuals have two or more samples tested, allowing to verify seroconversion or seroreversion. All the seroconversions happened between the first and second blood collection.

To better elucidate these data, the volunteers were categorized as nonhospitalized (asymptomatic and mild), and hospitalized (moderate and severe). The latter group was followed during the hospitalization, therefore, they entered the study presenting symptoms, and their sampling occurred more frequently (median of 6 days between collections, IQR 5-12) and during a shorter time, as they were not followed after discharge. In this group, 28 volunteers (80%) re- 3.4 | S1, S2, and N IgA and IgG against SARS-CoV-2

To assess the IgG and IgA separated responses to these antigens (S1, S2, or N) we evaluated the higher quantification of ViraChip ® units. It was verified that the antibody level increased along with severity, as shown in Figure 1 . The severe group presented higher quantifications than the other groups (p < 0.0001 for all parameters). If we compare the recognition of the antigens in each group, there is no statistical difference in IgA response. Considering IgG response, there is no difference in asymptomatic volunteers, but in the mild and moderate groups, there is a superiority of IgG-S1 compared with IgG-S2 (p < 0.01 and p < 0.05, respectively), and in severe volunteers, IgG-S1 was superior to IgG-N and IgG-S2 (p < 0.01 for both). Death occurred among 10 of the hospitalized volunteers, as shown in Figure 2 . There is no statistical difference when these two groups are compared.

The deceased volunteers achieved the maximum antibody response slightly earlier than the recovered volunteers, however, there is no statistical difference between the groups. The deceased volunteers took 7 days (IQR 4-9) to reach maximal quantification for all parameters, while the recovered group took 9 days (IQR 6-12) to achieve maximum IgG-S1, IgG-N, IgA-N, and IgA-S2, and 8 days (IQR 6-12) for IgG-S2 and IgA-S1.

Several studies had been conducted to describe the immune response of patients exposed to SARS-CoV-2, which helps to understand the immunopathogenesis of the disease. The immune response seems to vary extensively among COVID-19 patients and spiratory tract, would be followed by persistent viremia. 16, 17 Therefore, it is possible that a continuous synergism between the host's immune system and SARS-CoV-2 infection define the disease presentation. 13 We assessed the IgA and IgG responses to S1, N, and S2 antigens of SARS-CoV-2 of four different groups (asymptomatic, mild, moderate, or severe COVID-19). Although it was not the main objective of this study, we verified statistical significance in hospitalized patients presenting comorbidities, as the literature describes. 18 Obesity was strongly associated with hospitalization (p < 0.0001). A different study that enrolled IIER patients confirmed the result. 19 In COVID-19, obesity increases the chance of the patient being hospitalized in intensive care units, it is usually associated with other aggravating factors, like hypertension and diabetes; and has been related to immunological impairments, like increased inflammation and decrease of Treg activity, which may contribute to inadequate immune response. 20 This information highlights the need to observe comorbidities in the risk assessment of COVID-19 patients.

When the absolute number of positive samples was analyzed, regardless of the severity classification ( (IgA and IgG) to three antigens tested (S1, N, and S2) increased according to disease severity ( Figure 1 ). COVID-19 patients showed higher IgA and IgG levels in severe cases when compared with asymptomatic and mild patients, which is also seen in Carsetti et al. 16 study.

Some studies described an N-biased IgG response in hospitalized patients of COVID-19, which would reflect the persistent viremia, because of the higher quantity of N antigen incorporated into the virion. 14,28 However, in our study, the IgG-S1 parameter was detected in statistically higher quantity compared with IgG-N and IgG-S2 in the severe group (p < 0.01); in asymptomatic, mild, and moderate groups this parameter overcame the others, as well. The S protein is one of the main immunogenic antigens of SARS-CoV-2, therefore, its dominance on the humoral response can be expected. 3 This quantification analysis does not reflect the actual functionality of antibodies. For example, anti-RBD has been related to IgA and IgG neutralization capacity, 29, 30 and needed to decrease the viral load of severe patients in the Silva et al. 15 study. Comparing decease and recovery outcomes, Atyeo et al. 14 pointed an S-biased response in the recovered group.

The time to reach the maximum antibody quantity has been investigated, but disagreeing results were seen in the literature: the indication of fatality in Hashem et al. 28 was reaching higher anti-S1

and anti-N IgG responses at the beginning of symptoms; while in Lucas et al. 31 deceased patients presented a delayed antibody response. In this study, the deceased patients reached the higher humoral response within 7 days, slightly earlier than the recovered ones, which varied from 8 to 9 days. However, disagreeing results in the literature suggest that the kinetics of humoral response as an indicator of the outcome should be further investigated.

Interestingly, some of the hospitalized patients presented low maximum antibody quantification ( Figure 2 ) and were able to recover from COVID-19. We cannot properly evaluate the particularities that lead to it without further investigations, but it has been suggested that different arms of immune response participate in the control of the disease: the quality of innate immunity, with activation of Natural Killer (NK) cells, has been related with resistance to infection 32 ;

phagocytosis and complement-fixing activity were remarkable features of recovered patients 14 ; convalescent patients with almost undetectable antibody titers presented T cell immune response to S and Membrane proteins 33 ; higher frequencies of Treg cells were found in nonhospitalized patients, compared with hospitalized cases. 34 These studies indicate that the humoral response, especially antibody titers, despite its importance, should not be the only goal for immunity against SARS-CoV-2. Although the information in B cell memory is not available, the functional characteristics of antibodies have been investigated. The avidity index, measuring the strength of binding between the paratope and epitope, suggests an affinity maturation of the immune response with time. 35 Studies following COVID-19 patients point to overall low avidity of antibodies. 19 The incomplete avidity maturation followed by a decay in antibodies titers is common in coronaviruses response and could explain reinfections and repetitive outbreaks. 36 Considering it all, it is important to highlight that positive serology following COVID-19 by itself is not a definitive marker of protection.

World Health Organization. WHO coronavirus disease (COVID-19) dashboard

COVID-19 Antibody tests: a valuable public health tool with limited relevance to individuals

Viral targets for vaccines against COVID-19

COVID-19: significance of antibodies

COVID-19: The first documented coronavirus pandemic in history

Clinical course and risk factors for mortality of adult inpatients with COVID-19 in Wuhan, China: a retrospective cohort study

Prevalence of antibodies against SARS-CoV-2 in professionals of a public health laboratory at São Paulo, SP, Brazil. bioRxiv

Guia de vigilância epidemiológica -COVID-19

Boletim Epidemiológico Especial n01 do Ministério da Saúde: Infecção Humana pelo Novo Coronavírus (2019-nCoV)

Throat wash as a source of SARS-CoV-2 RNA to monitor community spread of COVID-19. medRxiv

Detection of 2019 novel coronavirus (2019-nCoV) by real-time RT-PCR

COVID-19: unanswered questions on immune response and pathogenesis

Distinct early serological signatures track with SARS-CoV-2 survival

Saliva viral load is a dynamic unifying correlate of COVID-19 severity and mortality. medRxiv

Different innate and adaptive immune responses to SARS-CoV-2 infection of asymptomatic, mild, and severe cases

The central role of the nasal microenvironment in the transmission, modulation, and clinical progression of SARS-CoV-2 infection

Epidemiological, comorbidity factors with severity and prognosis

Serological assessment of COVID-19 patients in Brazil: levels, avidity, and subclasses of IgG against RBD. Res Sq

Individuals with obesity and COVID-19: a global perspective on the epidemiology and biological relationships

Factors associated with prolonged viral RNA shedding in patients with COVID-19

Diabetes mellitus is a risk factor for prolonged SARS-CoV-2 viral shedding in lower respiratory tract samples of critically ill patients

Coronavirus Disease 2019 pneumonia in immunosuppressed renal transplant recipients: a summary of 10 confirmed cases in Wuhan, China

Antibody dynamics, seroreversion and persistence after SARS-CoV-2: another answer

Decline in SARS-CoV-2 antibodies after mild infection among frontline health care personnel in a multistate hospital network -12 states

Seroprevalence of SARS-CoV-2 antibodies, associated epidemiological factors and antibody kinetics among healthcare workers in Connecticut

Persistence and decay of human antibody responses to the receptor binding domain of SARS-CoV-2 spike protein in COVID-19 patients

Early humoral response correlates with disease severity and outcomes in COVID-19 patients

Immunodominant B cell epitope in a hotspot mutation site and mechanism of immune escape for SARS-CoV-2. medRxiv

Temporal maturation of neutralizing antibodies in COVID-19 convalescent individuals improves potency and breadth to circulating SARS-CoV-2 variants

Delayed production of neutralizing antibodies correlates with fatal COVID-19

Immunogenetics of resistance to SARS-CoV-2 infection in discordant couples

Cellular immunity in COVID-19 convalescents with PCR-confirmed infection but with undetectable SARS-CoV-2-specific IgG

Imbalance of regulatory and cytotoxic SARS-CoV-2-Reactive CD4+ T cells in COVID-19

Avidity assay to test functionality of anti-SARS-CoV-2 antibodies

The potential significance of high avidity immunoglobulin G (IgG) for protective immunity towards SARS-CoV-2

Humoral response to spike S1 and S2 and nucleocapsid proteins on microarray after SARS-CoV-2 infection